Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32:187–192, 2009
The following statement should appear in the acknowledgments concerning the potential dualities of interest of Richard Bergenstal: R.B. participates in clinical research or has served on a scientific advisory board for Amylin, Merck, Pfizer, ResMed, Valeritas, Eli Lilly, Novo Nordisk, sanofi-aventis, MannKind, Intuity, Roche, LifeScan, Abbott, Bayer, and Medtronic. R.B. receives no personal compensation for these activities; all contracts are through the nonprofit Park Nicollet Institute. R.B. holds stock in Merck through a family inheritance and is an officer within the American Diabetes Association.
The online version reflects these changes.
